Articles
11 June 2009
Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
https://doi.org/10.4081/hmr.v3i1.537

Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
212
Views
129
Downloads

Authors

R Advani
support@pagepress.org
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and complex lymphoproliferative disorder. The lack of standard and effective treatments to date poses significant challenges for physicians treating patients with AITL. There is little consensus on the optimal chemotherapy regimen in either the frontline treatment or relapsed setting. In several series the median survival of AITL patients has been estimated to be between 11 and 30 months, with only 30% of patients surviving more than 2 years.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.537